** Shares in Genfit GNFT.PA jump 7.5% after the drug
developer's shareholders and bondholders approve its convertible
bonds (OCEANEs) buyback
** "EUR 85.7 million convertible debt will be cancelled by
spending only EUR 47.48 million following buyback settlement
operations to take place this week", the company said
urn:newsml:reuters.com:*:nGNE9Xbhqr
** The group also extended the maturity of its remaining
OCEANEs to end 2025, allowing Genfit to implement its new
corporate strategy
** Among the 8 analysts that cover Genfit, the breakdown of
recommendations is four "strong buy" or "buy," and four "hold"
(Charles.regnier@thomsonreuters.com)